To add on to turtle's question, what are sales projections for the MF drug, if approved? Also, INCY has all U.S. rights to the drug, while NVS has ex-U.S. rights, correct? What are the economics due INCY from NVS ex-U.S.? And does INCY have the full capabilities to market the drug on their own in the U.S.? (That's obviously a big deal having full U.S. rights to the drug, assuming it is projected to potentially be a big seller.)
And I do think there is nice potential for the RA drug partnered with LLY. Curious about the economics due INCY on that drug as well as I don't recall off-hand.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.